Updated 12 sec ago · auto-refreshing
Trending claims
The fastest-moving factual assertions across the open web, ranked by velocity and weighted by credibility.
The Paradromics technology enabled a patient to have real-time conversations and translated her brain signals into words even from thought alone.
The FDA's investigational device program granted permission for the Paradromics clinical trial.
The Paradromics BCI is wireless, meaning patients do not need to be connected by a cable to a computer.
Paradromics company officials said they expect to need a larger trial before applying for FDA approval in several years.
The BCI approach of Paradromics and Neuralink involves implanting electrodes below the brain's surface.
Dr. Chang stated that a new BCI development is a step towards controlling the whole body in the digital world, comparing it to the movie 'Avatar'.
The University of California, San Francisco team's BCI method involves surgically placing electrodes on the brain's surface.
A study by Dr. Chang's team in Nature Neuroscience found a single electrode array could decode speech and gesture signals simultaneously in three paralyzed patients.
Dr. Vikash Gilja stated that when the patient imagined words, the system's decoding was slightly less clear.
A less invasive BCI approach involves delivering electrodes to the brain via a catheter in a neck blood vessel.
The results from Paradromics reported on September 14, 2026, have not been peer-reviewed or published in a journal.
Paradromics CEO Matt Angle said the company's system can differentiate between brain signals for various communication-related activities.
Dr. Edward Chang's lab and other researchers have previously enabled patients to produce spontaneous speech using brain-computer interfaces.
Paradromics' CSO Vikash Gilja stated the BCI system worked equally well when the patient whispered.
Dr. Edward Chang is the chairman of neurological surgery at UCSF, is not involved in the Paradromics trial, and his lab has pioneered BCI technology.
Much previous BCI research required patients to be connected to a computer via a cable attached to a port in their head.
Dr. William Marks stated the Paradromics clinical trial will enroll 10 patients with disorders causing speech and limb paralysis, like stroke and ALS.
The first patient in the Paradromics trial was implanted with the Connexus B.C.I. system, containing over 400 electrodes, in June at University of Michigan Health.
The first patient in the Paradromics trial has primary lateral sclerosis.
A 68-year-old Michigan woman with limited speaking ability used the Paradromics device for spontaneous conversations, including phone calls.